- Home
- MYI vs TNGX Comparison
MYI vs TNGX Comparison
Compare MYI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYI
- TNGX
- Stock Information
- Founded
- MYI 1992
- TNGX 2014
- Country
- MYI United States
- TNGX United States
- Employees
- MYI N/A
- TNGX N/A
- Industry
- MYI Investment Bankers/Brokers/Service
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MYI Finance
- TNGX Health Care
- Exchange
- MYI Nasdaq
- TNGX Nasdaq
- Market Cap
- MYI 701.9M
- TNGX 723.2M
- IPO Year
- MYI N/A
- TNGX N/A
- Fundamental
- Price
- MYI $10.50
- TNGX $6.90
- Analyst Decision
- MYI
- TNGX Strong Buy
- Analyst Count
- MYI 0
- TNGX 6
- Target Price
- MYI N/A
- TNGX $10.00
- AVG Volume (30 Days)
- MYI 256.7K
- TNGX 1.9M
- Earning Date
- MYI 01-01-0001
- TNGX 08-05-2025
- Dividend Yield
- MYI 4.81%
- TNGX N/A
- EPS Growth
- MYI N/A
- TNGX N/A
- EPS
- MYI N/A
- TNGX N/A
- Revenue
- MYI N/A
- TNGX $24,296,000.00
- Revenue This Year
- MYI N/A
- TNGX N/A
- Revenue Next Year
- MYI N/A
- TNGX N/A
- P/E Ratio
- MYI N/A
- TNGX N/A
- Revenue Growth
- MYI N/A
- TNGX N/A
- 52 Week Low
- MYI $9.32
- TNGX $1.03
- 52 Week High
- MYI $11.70
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- MYI 55.04
- TNGX 56.63
- Support Level
- MYI $10.43
- TNGX $6.60
- Resistance Level
- MYI $10.52
- TNGX $7.42
- Average True Range (ATR)
- MYI 0.08
- TNGX 0.47
- MACD
- MYI -0.00
- TNGX -0.04
- Stochastic Oscillator
- MYI 68.18
- TNGX 57.20
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.